MIT Tests Magnetic Nanoantennas Against Drug-Resistant Glioblastoma

MIT researchers developed nanoantennas about 150 nanometers in size that can be activated by a low-frequency magnetic field to target drug-resistant glioblastoma cells. In preclinical laboratory tests and in mice, the technology reduced tumor growth, prolonged survival, and showed no detectable damage to healthy tissue or major organs.

• The HITMAN technology eliminated 52.2% of drug-resistant glioblastoma cells in laboratory tests.
• In mice, the therapy extended median survival by over 50% and significantly slowed tumor growth.
• The nanoantennas could be injected through the skull or administered using circulatronics technology, although both possibilities are still in the experimental phase.

🧠⚡ MIT tests nanoantennas against drug-resistant glioblastoma

HITMAN eliminated 52.2% of tumor cells and outperformed temozolomide by 5 times.

In mice, it prolonged survival by over 50% with no detectable damage.

Still in preclinical phase. pic.twitter.com/qNWjWkyiQ1

--- Diario฿itcoin (@DiarioBitcoin) September 10, 2026

MIT Tests Magnetic Nanoantennas Against Drug-Resistant Glioblastoma

MIT researchers developed a platform of injectable nanoantennas that can be wirelessly activated from outside the body to target chemotherapy-resistant glioblastoma tumors. In experiments with patient-derived cells and animal models, the technology reduced brain cancer growth and prolonged survival without detectable damage to surrounding healthy tissue.

Glioblastoma is among the most aggressive and difficult-to-treat cancers, with a median survival of only 12 to 15 months even under the best available care. Its infiltrative nature complicates complete removal, while radiotherapy and chemotherapy often face resistance, and immunotherapy encounters obstacles in a tumor environment that weakens the immune response.

An Electric Therapy Targeted at the Tumor

The MIT Media Lab team named the platform HITMAN, an acronym for High-Intensity Targeted Magnetic Antenna Nano-therapy. Each device measures approximately 150 nanometers, about one-hundredth the width of a human hair, and is designed to generate localized intervention within the brain.

As explained by Deblina Sarkar, associate professor and holder of the AT&T Career Development Chair at the MIT Media Lab, laboratory and animal trials showed a significant reduction in tumor growth and prolonged survival, with no detectable side effects. The researcher also leads the Nano-Cybernetic Biotrek group, responsible for the development described in an open-access article published in Science Advances.

Activation occurs via a low-frequency magnetic field, no more than 200 kHz, which can penetrate the skull and brain tissue without generating heat capable of damaging nearby structures. This field moves magnetostrictive components within the nanoantenna, causing deformation of a piezoelectric film and producing concentrated electric fields around the device.

Researchers assert that these fields alter the bioelectric currents and fields inherent to tumor cells. The process triggers protein unfolding, membrane damage, and endoplasmic reticulum stress, ultimately reducing the production of functional proteins and leading to cell death.

Results Against Resistant Cells

To evaluate the platform in a clinically more realistic version of the disease, the team worked with tumor tissue obtained from patients diagnosed with aggressive and chemotherapy-resistant glioblastoma at Mayo Clinic. From that material, scientists cultured cells in the laboratory and compared the effect of HITMAN with that of temozolomide, one of the standard drugs used against this cancer.

The nanoantennas eliminated 52.2% of drug-resistant cancer cells, a result more than five times that achieved by temozolomide in the same tests. At the same time, healthy neurons and astrocytes, cells that help support brain function, remained unharmed during the experiment.

The team also conducted controls to determine whether the result truly depended on the combination of the device and magnetic activation. Cells exposed to nanoantennas without a magnetic field, as well as those subjected only to the field, did not show the same antitumor effect, reinforcing the attribution of the result to the full operation of HITMAN.

The authors relate the selectivity to the characteristics of cancer cells, whose rapid proliferation increases the demand for protein folding and modifies the composition of their membranes and organelles. This vulnerability would allow targeting glioblastoma with localized electric fields while preserving healthy cells near the tumor.

Testing in Animal Models

After cellular trials, researchers implanted tumor cells derived from patients into the brains of mice. These orthotopic models, which reproduce cancer in the corresponding brain region, are considered an important reference for preclinical research on nervous system tumors.

In treated animals, HITMAN substantially inhibited tumor growth and prolonged median survival by more than 50%. The team reported that they found no detectable toxicity in major organs such as the kidneys, liver, spleen, lungs, and heart, nor in the healthy brain tissue surrounding the intervened area.

Another experiment measured the ability of cancer cells to form new colonies after receiving treatment. Control groups produced between 112 and 150 colonies, while the experimental group recorded only 26, a result that researchers consider a sign of potential utility in reducing tumor recurrence and metastasis.

These findings still belong to a preclinical stage and do not yet demonstrate safety or efficacy in humans. The difference is particularly important in glioblastoma because the complexity of brain tissue, the irregular distribution of tumor cells, and the difficulty in reaching all affected areas can modify the performance observed in mice.

The Path Towards Potential Clinical Application

In a clinical scenario, nanoantennas could be injected directly through the skull and activated without an external physical connection. The design aims to reduce the invasiveness of the intervention, although any transfer to patients would require evaluating the distribution of the devices, the precision of activation, their permanence in the body, and potential cumulative effects.

Sarkar noted that a technology previously developed by his lab could further simplify administration. In 2025, the group presented the so-called circulatronics, electronic devices integrated with living cells to avoid immune system attack and facilitate crossing the blood-brain barrier, according to demonstrations conducted in preclinical studies.

The proposal is relevant because the blood-brain barrier limits the access of numerous medications to the brain and constitutes one of the central obstacles to treating neurological tumors. However, the possibility of nanoantennas traveling from an injection in the arm to a target region is still part of an experimental line and not an available therapy.

The work was led by Deblina Sarkar along with Monochura Saha, Ishaq Khan, Baju Joy, Shun Ying Chen, Hao-Tung Yang, Preet Patel, Pengrui Zhang, and Faheem Azeemi, who were affiliated with MIT at different times as researchers, graduate students, or undergraduate students. The platform offers a precision alternative against a cancer whose infiltration complicates surgery, but the next steps will need to confirm whether its results can be sustained in controlled clinical studies.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.